Citation

Lücking U, Wortmann L, Wengner AM, Lefranc J, Lienau P, Briem H, Siemeister G, Bömer U, Denner K, Schäfer M, Koppitz M, Eis K, Bartels F, Bader B, Bone W, Moosmayer D, Holton SJ, Eberspächer U, Grudzinska-Goebel J, Schatz C, Deeg G, Mumberg D, von Nussbaum F.: Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem, Volume 63 (13), 2020

Authors

Bader B, Bartels F, Bömer U, Bone W, Briem H, Deeg G, Denner K, Eberspächer U, Eis K, Grudzinska-Goebel J, Holton SJ, Koppitz M, Lefranc J, Lienau P, Lücking U, Moosmayer D, Mumberg D, Schäfer M, Schatz C, Siemeister G, von Nussbaum F., Wengner AM, Wortmann L

Journal

J Med Chem

Year

2020

DOI

10.1021/acs.jmedchem.0c00369

PubMed

32502336

Machine-readable

REST APIRDF